SKIN CLEARANCE is meant by: 69% Psoriasis Area and Severity Index (PASI) 100, an exploratory endpoint, achieved in PsO patients receiving Cosentyx 300 mg (n=80) vs 22.4% of patients receiving narrowband ultraviolet B (nb-UVB) phototherapy (n=80) (p<0.0001) through Week 52. The primary endpoint of PASI 90 response at week 52 for Cosentyx 300 mg vs nb-UVB was met (91.1% vs 42.3% respectively, p<0.0001).

FURTHER is meant by: 90% of PsO patients with PsA (n=191) taking Cosentyx 300 mg showed no radiographic progression through Year 2 (observational data, no statistical testing). The primary endpoint of proportion of patients achieving ACR20 response at Week 16 was met (Cosentyx 300 mg 62.6% vs placebo 27.4%, p<0.0001).